Donor Nucleic Acid Design for Higher Homologous Recombination

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing genome-editing systems face low efficiency in homologous recombination, requiring laborious and time-consuming screening of clonal cells to identify those with the desired genotype.

Innovation Solution

A method involving a CRISPR complex to create double-strand breaks in cells, followed by targeted delivery of donor nucleic acid molecules with matched termini and nuclease-resistant groups, optimizing the timing and amount of donor nucleic acid introduction to enhance homologous recombination efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional genome-editing systems are used to perform homologous recombination, then genetic modification can be achieved, but the efficiency is low requiring extensive screening of clonal cells

Engineering Contradiction:
Improvehomologous recombination efficiencyVSAvoidtime required to identify correctly edited cells
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent modifies key parameters of the homologous recombination process including: (1) optimizing the ratio of donor nucleic acid to target locus, (2) adjusting the timing of donor nucleic acid delivery relative to CRISPR complex formation, (3) modifying donor nucleic acid structure with asymmetric termini and nuclease-resistant groups, and (4) controlling the concentration of CRISPR components. These parameter changes collectively enhance homologous recombination efficiency to at least 20% of cells, dramatically reducing the time and effort required to identify correctly edited cells.

Inventive Principle:
Principle #35Parameter changes

2Ease of operation

If donor nucleic acid is delivered simultaneously with CRISPR complex, then the process is simplified, but homologous recombination efficiency decreases

Engineering Contradiction:
Improvesimplicity of delivery processVSAvoidhomologous recombination efficiency
Core Design Contradiction:
Ease of operationVSProductivity

Solution Approach 1:

The patent implements a two-stage delivery process where the CRISPR complex is introduced into cells first to establish the double-strand break and prepare the target locus. After a controlled interval (optimally 1-4 hours), the donor nucleic acid is then delivered. This preliminary action of creating the break site before introducing the repair template maximizes homologous recombination efficiency, achieving at least 20% edited cells while maintaining operational simplicity through standardized timing protocols.

Inventive Principle:
Principle #10Preliminary action

3Device complexity

If standard donor nucleic acid molecules are used, then the system is simpler, but homologous recombination efficiency is limited

Engineering Contradiction:
Improvecomplexity of donor nucleic acid structureVSAvoidhomologous recombination efficiency
Core Design Contradiction:
Device complexityVSProductivity

Solution Approach 1:

The patent applies local quality modifications to specific regions of the donor nucleic acid molecule: (1) asymmetric termini design where the 5' and 3' ends have different structures and lengths to match the polarity of the double-strand break, (2) incorporation of nuclease-resistant chemical groups (such as phosphorothioate modifications) at critical positions to protect against degradation, and (3) optimization of homology arm lengths and sequences at the termini. These localized structural enhancements significantly improve homologous recombination efficiency to at least 20% of cells while maintaining overall system simplicity.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances homologous recombination efficiency to at least 20% of cells, reducing the time and effort required to identify correctly edited cells.

Implementation Method 1

contacting the population of cells with a nucleic acid cutting entity under conditions that allow for the generation of double-stranded break at a target locus in nucleic acid present inside cells

Methodology Applied
Scientific EffectCRISPR-mediated nucleic acid cleavage: Enzyme

Implementation Method 2

contacting the cells with the donor nucleic acid molecule under conditions that allow for homologous recombination to occur at the target locus in at least 20% of the cells

Methodology Applied
Scientific EffectHomologous recombination: Chemical Bonding

Data Source

PatentEP3872177B1Compositions and methods for enhancing homologous recombination
Publication Date: 2025.11.26 LIFE TECHNOLOGIES CORP
  • EP3872177B1 patent drawingFigure 1
  • EP3872177B1 patent drawingFigure 2
  • EP3872177B1 patent drawingFigure 3

AI summary

The present disclosure generally relates to compositions and methods for improving the efficiency of homologous recombination. In particular, the disclosure relates to reagents and the use of such reagents.